

ELMMB Formulary Update

October 2018

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Evolocumab** – *not recommended for the prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin.*
- **Tadalafil® once daily** - (Cialis®) erectile dysfunction
- **Cenegermin** – neurotrophic keratitis scleritis - *not recommended by [NICE TA532](#)*
- **Nivolumab** – *locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy – not recommended by [NICE TA530](#)*

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **5% Imiquimod cream (Aldara®) & 5% Fluorouracil cream (Efudix®):** *for the treatment of small superficial basal-cell carcinoma in adults*
- **Crizotinib **** - *ROS1-positive advanced non-small-cell lung cancer: an option in line with [NICE TA529](#)*
- **Dupilumab** - *moderate to severe atopic dermatitis: an option in [NICE TA534](#) Blueteq form required.*
- **Alectinib** – *untreated ALK-positive advanced non-small-cell lung cancer: an option in [NICE TA536](#)*
- **Dinutuximab beta**** - *neuroblastoma: an option in [NICE TA538](#)*
- **Hydroquinone 5%, hydrocortisone 1% & tretinoin 0.1% in non-aqueous gel (Pigmanorm®):** *treatment of melasma (unlicensed)*
- **Pembrolizumab**** - *untreated PD-L1-positive metastatic non-small-cell lung cancer: an option in [NICE TA531](#)*
- **Atezolizumab**** - *untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable: an option in line with [NICE TA492](#) (updated)*
- **Ixekizumab** – *active psoriatic arthritis after inadequate response to DMARDs: an option in [NICE TA537](#). Blueteq form required.*
- **Nirapanib**** - *maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer: an option in [NICE TA528](#)*
- **Pembrolizumab**** - *untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable: an option in [NICE TA522](#) (updated)*
- **Lenvatinib and sorafenib**** - *differentiated thyroid cancer after radioactive iodine: an option in line with [NICE TA535](#)*
- **Lutetium (177Lu) oxodotreotide**** – *unresectable or metastatic neuroendocrine tumours: an option in [NICE TA539](#)*

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Paravit®CF** – *dietary management of patients with cystic fibrosis (specialist initiation)*
- **Testosterone gel** – Testogel® pump replaces sachets
- **Methylphenidate** – local shared care updated to include XaggitinXL MR tablets
- **Vitamin D treatment dose for paediatrics** – *GPs to prescribe initial dose on request from specialist then ongoing maintenance to be purchased under self-care.*

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Mesalazine suppositories** – *Salofalk® replaces Asacol® brand (discontinued)*

Guidelines/Other

- [ELHE Pathway for the prevention of stroke & systemic embolism in non-valvular AF.](#)
- [Medicines Management Board Minutes](#)
- [Drug Safety Updates](#)
- [ELHE Phenylketonurea Position Statement.](#)
- [NICE Bites](#)
- [Shared Care Guidelines](#)
- [Prescribing Hot Topics](#)
- [ELHT Syringe Pump Policy – updated to include Ranitidine monograph.](#)
- [E-learning hub](#)
- [Training for Care Home Staff](#)
- [Adult Social Care Training Programme 2018](#)